CTOs on the Move

DiCE Molecules

www.dicemolecules.com

 
At DiCE Molecules, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

DiCE Molecules raised $54M on 12/18/2020
DiCE Molecules raised $80M on 01/08/2021

Similar Companies

Phio Pharmaceuticals

Developing the next generation of immuno-oncology therapeutics

Caladrius

Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.

Shady Grove Adventist Hospital

Shady Grove Adventist Hospital is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ALX Oncology

ALX Oncology is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.

IMV

IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and other serious diseases.